{"id":832920,"date":"2022-11-07T18:00:55","date_gmt":"2022-11-07T17:00:55","guid":{"rendered":"https:\/\/bebeez.it\/non-categorizzato\/bluebird-bio-reports-third-quarter-2022-financial-results-and-highlights-operational-progress\/"},"modified":"2022-11-07T18:00:55","modified_gmt":"2022-11-07T17:00:55","slug":"bluebird-bio-reports-third-quarter-2022-financial-results-and-highlights-operational-progress","status":"publish","type":"post","link":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-third-quarter-2022-financial-results-and-highlights-operational-progress\/","title":{"rendered":"bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress"},"content":{"rendered":"- Commercial launch of ZYNTEGLO\u00ae (betibeglogene autotemcel) underway; on track for first apheresis in the fourth quarter of 2022 -\n\n\n- Chris Krawtschuk appointed chief financial officer -\n\n\n- Ended quarter with $186M in cash and cash equivalents, marketable securities and restricted cash -\n\nSOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (\u201cbluebird bio\u201d or the \u201cCompany\u201d) today reported financial results and business highlights for the third quarter ended September 30, 2022 and shared recent operational progress.\n\n\n\n\"The third quarter officially launched bluebird bio as a commercial gene therapy company, following FDA approvals of ZYNTEGLO for beta-thalassemia and SKYSONA for cerebral adrenoleukodystrophy,\" sai
Abbonati<\/a> o Accedi<\/a> per leggere il resto di questo contenuto.<\/div><\/div>","protected":false},"excerpt":{"rendered":"

– Commercial launch of ZYNTEGLO\u00ae (betibeglogene autotemcel) underway; on track for first apheresis in the fourth quarter of 2022 – – Chris Krawtschuk appointed chief financial officer – – Ended quarter with $186M in cash and cash equivalents, marketable securities and restricted cash – SOMERVILLE, Mass.–(BUSINESS WIRE)–bluebird bio, Inc. (NASDAQ: BLUE) (\u201cbluebird bio\u201d or the […]<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[49625],"tags":[],"settori":[],"slider_categorie_and_home_page":[],"class_list":["post-832920","post","type-post","status-publish","format-standard","hentry","category-private-capital-in-north-america"],"acf":[],"yoast_head":"\nbluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress - BeBeez<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-third-quarter-2022-financial-results-and-highlights-operational-progress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress - BeBeez\" \/>\n<meta property=\"og:description\" content=\"- Commercial launch of ZYNTEGLO\u00ae (betibeglogene autotemcel) underway; on track for first apheresis in the fourth quarter of 2022 - - Chris Krawtschuk appointed chief financial officer - - Ended quarter with $186M in cash and cash equivalents, marketable securities and restricted cash - SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (\u201cbluebird bio\u201d or the […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-third-quarter-2022-financial-results-and-highlights-operational-progress\/\" \/>\n<meta property=\"og:site_name\" content=\"BeBeez\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-07T17:00:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"683\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-third-quarter-2022-financial-results-and-highlights-operational-progress\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-third-quarter-2022-financial-results-and-highlights-operational-progress\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress\",\"datePublished\":\"2022-11-07T17:00:55+00:00\",\"dateModified\":\"2022-11-07T17:00:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-third-quarter-2022-financial-results-and-highlights-operational-progress\/\"},\"wordCount\":2618,\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"articleSection\":[\"Private capital in North America\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-third-quarter-2022-financial-results-and-highlights-operational-progress\/\",\"url\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-third-quarter-2022-financial-results-and-highlights-operational-progress\/\",\"name\":\"bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress - BeBeez\",\"isPartOf\":{\"@id\":\"https:\/\/15.161.165.86\/#website\"},\"datePublished\":\"2022-11-07T17:00:55+00:00\",\"dateModified\":\"2022-11-07T17:00:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-third-quarter-2022-financial-results-and-highlights-operational-progress\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-third-quarter-2022-financial-results-and-highlights-operational-progress\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-third-quarter-2022-financial-results-and-highlights-operational-progress\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bebeez.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/15.161.165.86\/#website\",\"url\":\"https:\/\/15.161.165.86\/\",\"name\":\"BeBeez\",\"description\":\"BeBeez\",\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/15.161.165.86\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/15.161.165.86\/#organization\",\"name\":\"BeBeez\",\"url\":\"https:\/\/15.161.165.86\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"contentUrl\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"width\":309,\"height\":122,\"caption\":\"BeBeez\"},\"image\":{\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress - BeBeez","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-third-quarter-2022-financial-results-and-highlights-operational-progress\/","og_locale":"en_US","og_type":"article","og_title":"bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress - BeBeez","og_description":"- Commercial launch of ZYNTEGLO\u00ae (betibeglogene autotemcel) underway; on track for first apheresis in the fourth quarter of 2022 - - Chris Krawtschuk appointed chief financial officer - - Ended quarter with $186M in cash and cash equivalents, marketable securities and restricted cash - SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (\u201cbluebird bio\u201d or the […]","og_url":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-third-quarter-2022-financial-results-and-highlights-operational-progress\/","og_site_name":"BeBeez","article_published_time":"2022-11-07T17:00:55+00:00","og_image":[{"width":683,"height":242,"url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-third-quarter-2022-financial-results-and-highlights-operational-progress\/#article","isPartOf":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-third-quarter-2022-financial-results-and-highlights-operational-progress\/"},"author":{"name":"","@id":""},"headline":"bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress","datePublished":"2022-11-07T17:00:55+00:00","dateModified":"2022-11-07T17:00:55+00:00","mainEntityOfPage":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-third-quarter-2022-financial-results-and-highlights-operational-progress\/"},"wordCount":2618,"publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"articleSection":["Private capital in North America"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-third-quarter-2022-financial-results-and-highlights-operational-progress\/","url":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-third-quarter-2022-financial-results-and-highlights-operational-progress\/","name":"bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress - BeBeez","isPartOf":{"@id":"https:\/\/15.161.165.86\/#website"},"datePublished":"2022-11-07T17:00:55+00:00","dateModified":"2022-11-07T17:00:55+00:00","breadcrumb":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-third-quarter-2022-financial-results-and-highlights-operational-progress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-third-quarter-2022-financial-results-and-highlights-operational-progress\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-third-quarter-2022-financial-results-and-highlights-operational-progress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bebeez.it\/en\/"},{"@type":"ListItem","position":2,"name":"bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress"}]},{"@type":"WebSite","@id":"https:\/\/15.161.165.86\/#website","url":"https:\/\/15.161.165.86\/","name":"BeBeez","description":"BeBeez","publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/15.161.165.86\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/15.161.165.86\/#organization","name":"BeBeez","url":"https:\/\/15.161.165.86\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/","url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","contentUrl":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","width":309,"height":122,"caption":"BeBeez"},"image":{"@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/832920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/comments?post=832920"}],"version-history":[{"count":0,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/832920\/revisions"}],"wp:attachment":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/media?parent=832920"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/categories?post=832920"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/tags?post=832920"},{"taxonomy":"settori","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/settori?post=832920"},{"taxonomy":"slider_categorie_and_home_page","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/slider_categorie_and_home_page?post=832920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}